Simple sugar possible therapy for repairing myelin in multiple sclerosis — ScienceDaily

N-acetylglucosamine, a simple sugar found in human breast milk and sold as an over-the-counter dietary supplement in the United States, promotes myelin repair in mouse models and correlates with myelination levels in multiple sclerosis patients according to a new University of California, Irvine-led study.

Published in the Journal of Biological Chemistry, the study also demonstrates that in mice, delivering N-acetylglucosamine orally to lactating mothers drove primary myelination in their nursing offspring. N-acetylglucosamine is a simple sugar that is metabolically attached to proteins at the cell surface to control cellular function.

“We found that N-acetylglucosamine activates myelin stem cells to promote primary myelination and myelin repair,” said Michael Demetriou, MD, PhD, FRCP(C), professor of neurology, microbiology and molecular genetics at UCI School of Medicine and leader of the study. “Our data raises the intriguing possibility that N-acetylglucosamine may be a simple therapy to promote myelin repair in multiple sclerosis patients.”

Read More
Read More

AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference

The MarketWatch News Department was not involved in the creation of this content.

AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference

  • 50% of patients suffering from multiple sclerosis have one of the progressive forms of the disease, for which there is no satisfactory treatment to date
  • Masitinib, a tyrosine kinase inhibitor developed by AB Science, provides the first clinical evidence that targeting the innate immune system is an effective strategy for the treatment of progressive forms of multiple sclerosis.

AB Science SA (Euronext – FR0010557264 – AB), a pharmaceutical company specialized on the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has presented the world’s first key results from its Phase 2B/3 study (AB07002) evaluating its lead product, masitinib, in both progressive forms of multiple sclerosis1 during the 8th Joint Meeting of

Read More
Read More